Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Outcomes After UCBT in MDS Patients Evaluated
Biol Blood Marrow Transplant; 2017 Jun; Gerds, et al
For some with hematologic malignancies, umbilical cord blood transplantation (UCBT) can lead to long-term disease-free survival, according to a study involving 176 individuals. But success is tempered by a high transplantation-related mortality (TRM) rate.
Participants with myelodysplastic syndrome underwent UCBT between 2004 and 2013. They were a median 56 years of age, with IPSS-R risk levels ranging from very low to very high. Among the results:
- The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%.
- The 3-year probability of chronic GVHD was 28%.
- The probabilities of relapse and TRM at 3 years were 32% and 40%, respectively.
- Increasing IPSS-R score at the time of transplant and pretransplant comorbidities were each linked with worse TRM, and lower disease-free and overall survival.
- Those receiving reduced-intensity conditioning were nearly 4 times more likely to relapse.
- The effect of conditioning regimen intensity was the same regardless of IPSS-R score.
Gerds A, Woo A, Hu Z, et al. Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(6):971-979. doi:10.1016/j.bbmt.2017.03.014.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al